Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X by DAVA Oncology, adding:
“Exciting to see how the field is moving forward for our patients with SCLC!”
Quoting DAVA Oncology‘s post:
“Dr. Millie Das presented early-phase data on ABBV-706, a novel SEZ6-targeted ADC delivering a topo I payload.
In relapsed/refractory SCLC, ORR reached 60.9%. Safety manageable; biomarker role still unclear.
Combo trials with PD-1/platinum ongoing. “
More posts featuring Eric Singhi on OncoDaily.
